Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 24, 2017
Pharmacy Choice - News - Generic Drugs - July 24, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 76     Next >>     Go To Page:

7/24/17 - Aeterna Zentaris names new CEO and considers options for the firm [Oman News Agency]
The share price of Canada- based Aeterna Zentaris had shot up by nearly 200% to $3.01 by Friday lunchtime compared to Tuesdays close, with the company considering what to do following some good news. This news was the acceptance by the US Food and Drug Administration of the companys New Drug Application seeking approval of Macrilen for the evaluati
7/24/17 - Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin bevacizumab
By a News Reporter-Staff News Editor at Biotech Business Week Amgen and Allergan plc. announced that the Companies will discuss data supporting the ABP 215 Biologics License Application with the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration. ABP 215 is a biosimilar candidate to Avastin and is the first bevacizumab
7/24/17 - Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Files An 8-K Other Events
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Files An 8-K Other EventsITEM 8.01.Other Events. On July 24, 2017, Amphastar Pharmaceuticals, Inc. (Amphastar) announced in a press release that a federal jury delivered a unanimous verdict in favor of the Company in a lawsuit brought by Momenta Pharmaceuticals, Inc. and Sandoz Inc. in the U.S. Co
7/24/17 - Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation
By a News Reporter-Staff News Editor at Pharma Business Week Eli Lilly and Company has entered into a settlement agreement with generic companies to resolve pending patent litigation in the U.S. District Court for the Eastern District of Virginia regarding the Cialis unit dose patent. Patent expiration for Adcirca is still expected on November
7/24/17 - Merck Announces U.S. Launch Of RENFLEXIS, A Biosimilar Of Remicade
KENILWORTH- Merck& Co. Inc. announced Monday the U.S. launch of RENFLEXIS, a biosimilar of the originator biologic medicine Remicade. RENFLEXIS is the first medicine available in the U.S. under a global biosimilars development and commercialization agreement between Merck and Samsung Bioepis Co., Ltd.. The company noted that RENFLEXIS will be intro
7/24/17 - Merck Announces U.S. Launch of RENFLEXIS? (infliximab-abda), a Biosimilar of Remicade, for All Eligible Indications
Merck, known as MSD outside the United States and Canada, today announced the U.S. launch of RENFLEXIS?, a biosimilar of the originator biologic medicine Remicade. RENFLEXIS is the first medicine available in the U.S. under a global biosimilars development and commercialization agreement between Merck and Samsung Bioepis Co., Ltd.. RENFLEXIS will
7/24/17 - Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin1 (bevacizumab)
Pfizer Inc. today announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin , met its primary objective. PF-06439535 is being developed by Pfizer as a potential biosimilar to Avastin. The Pfizer biosimilars pipeline consists of eight distinct biosimilar molecules in mid to l
7/24/17 - Pfizer Says REFLECTIONS B7391003 Study Met Primary Objective
NEW YORK CITY- Pfizer Inc. said that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin, met its primary objective. PF-06439535 is being developed by Pfizer as a potential biosimilar to Avastin. Salomon Azoulay, Senior Vice President, Chief Medical Officer, Pfizer Essential Health sai
7/24/17 - Reducing the Need for Clinical Bioequivalence Endpoint Studies [Sudan Tribune]
Reviewing the recent approval of an abbreviated new drug application for a locally acting mometasone furoate nasal spray, the FDA highlighted the pivotal role played by an emerging analytical technology morphologically-directed Raman spectroscopy. 1 By combining automated imaging with Raman spectroscopy, MDRS enables determination of the size and..
7/24/17 - Samsung Bioepis Announces RENFLEXIS? (infliximab-abda) Now Available in the United States
RENFLEXIS? is the first drug developed by Samsung Bioepis to launch in the United States, following the US Food and Drug Administration s April 2017 approval RENFLEXIS?, a biosimilar referencing Remicade i, is only the third biosimilar to launch in the United States Merck, which is known as MSD outside of the United States and Canada, wil
7/24/17 - Samsung Bioepis biosimilar wins tentative approval in US [Tehran Times (Iran)]
The Lusduna Nexvue developed in cooperation with multinational drug company Merck Sharp and Dohme Corp. got the green light because it satisfied all regulatory rules for follow-on biologics of clinical and nonclinical safety, local here observers said. The drug, however, is being held back because of the remaining patent period controlled by French
7/22/17 - Anti-Thrombin Activators Market: Upcoming Demands and Growth Analysis 2024
Transparency Market Research Report Added "Anti-thrombin Activators Market" to its database.Albany, NY 07/21/2017 Anti-thrombin activators are widely accepted due to their role in reducing thrombus formation. Anticoagulants, anti-platelet drugs, and thrombolytic drugs are some of the different types of anti-thrombin activators available, whic
7/22/17 - MSDs Lantus biosimilar given conditional FDA approval [Sudan Tribune]
However, there is a hitch to the good news for MSD, it is dependent upon a patent infringement lawsuit brought against them by Sanofi. The tentative approval of Lusduna Nexvue is an important milestone, bringing us closer to offering this medicine to patients, said Sam Engel, Associate Vice President of Merck Clinical Research. For Sanofi, the appr
7/22/17 - Sen. Grassley, Bipartisan Drug Affordability Cosponsors Urge FDA Commissioner to Reform Anticompetitive Drug Practices
Senate Judiciary Committee Chairman Chuck Grassley alongside Senators Patrick Leahy, Mike Lee, and Amy Klobuchar are asking Food and Drug Administration Commissioner Scott Gottlieb to address anticompetitive practices currently used by some brand-name pharmaceutical companies to delay the manufacture and introduction of generic drugs in the...
7/22/17 - Sen. Leahy, Bipartisan Drug Affordability CREATES Act Cosponsors Urge FDA Commissioner to Reform Anticompetitive Drug Practices
U.S. Senator Patrick Leahy, joined by Senators Chuck Grassley, Amy Klobuchar, and Mike Lee, are asking Food and Drug Administration Commissioner Scott Gottlieb to address anticompetitive practices currently used by some brand-name pharmaceutical companies to delay the manufacture and introduction of generic drugs in the market. The senators wrote:
7/21/17 - 1.5 Billion Pharmaceutical Deal for Quebec [Sudan Tribune]
The French province of Quebec in Canada is in line to save an estimated 1.5 billion dollars over the next five years- due to the fact that it has reached a deal with a number of pharmaceutical companies, which will now mean that the price for generic drugs will be less expensive. The Health Minister Gaetan Barrette only announced conformation of th
7/21/17 - ACETO Subsidiary, Rising Pharmaceuticals, Announces Product Launches
ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, recently launched:. Ramipril Capsules, 1.25 mg, 2.5 mg, 5 mg, and 10 mg,
7/21/17 - Aeterna Zentaris Forms Strategic Review Committee and Appoints Michael Ward as CEO [Palestine News Agency (WAFA)]
Mr. Ward has over thirty years of executive and legal experience in the healthcare, pharmaceutical and technology industries. Most recently, Mr. Ward served as Chief Compliance& Legal Officer and Corporate Secretary for Sagent Pharmaceuticals, a global specialty generic pharmaceutical company, and led its sale to Nichi-Iko Pharmaceutical Co., Ltd.
7/21/17 - Biologics and Biosimilars Market Analysis with Key Players, Applications, Trends and Forecasts to 2022
Biologics and BiosimilarsMarketanalysis is provided for global market including development trends by regions, competitive analysis ofbiologics and biosimilars market. Most products being developed as biosimilars are rec...
7/21/17 - Breckenridge Announces Final Approval for Omeprazole Delayed-Release Capsules
By a News Reporter-Staff News Editor at Drug Week Breckenridge Pharmaceutical, Inc. announced it has received U.S. Food and Drug Administration final approval of its abbreviated new drug application for Omeprazole delayed-release capsules, USP, in 10 mg, 20 mg, 40 mg strengths, which will be manufactured and supplied by its parent company, Labora
7/21/17 - ENDO INTERNATIONAL PLC FILES (8-K) Disclosing Costs Associated with Exit or Disposal Activities
The Registrant's Board of Directors approved the 2017 U.S. Generic Pharmaceuticals restructuring initiative on July 18, 2017. As a result of the 2017 U.S. Generic Pharmaceuticals restructuring initiative, the Registrant's workforce is expected to be reduced by approximately 875 positions, including approximately 35 open positions, and the Registran
7/21/17 - Leahy And Bipartisan Drug Affordability CREATES Act Cosponsors Urge FDA Commissioner To Reform Anticompetitive Drug Practices
WASHINGTON- U.S. Senator Patrick Leahy, joined by Senators Chuck Grassley, Amy Klobuchar, and Mike Lee, are asking Food and Drug Administration Commissioner Scott Gottlieb to address anticompetitive practices currently used by some brand-name pharmaceutical companies to delay the manufacture and introduction of generic drugs in the market.
7/21/17 - Momenta Pharmaceuticals Announces Jury Verdict in Enoxaparin Sodium Injection Patent Litigation Against Amphastar
Momenta Pharmaceuticals, Inc. today announced that the jury in the District Court for the District of Massachusetts in Boston has issued its verdict finding that the Company s U.S. Patent No. 7,575,886, covering methods for the manufacturing of generic LOVENOX , was infringed, but invalid and unenforceable.. Momenta Pharmaceuticals is a biot
7/21/17 - New Ampicillins Findings Reported from University of Antioquia (Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of...
New Ampicillins Findings Reported from University of Antioquia. According to news reporting out of Medellin, Colombia, by NewsRx editors, research stated, "Previous studies have demonstrated that pharmaceutical equivalence and pharmacokinetic equivalence of generic antibiotics are necessary but not sufficient conditions to guarantee therapeutic...
7/21/17 - Pfizer's Inflectra, Takeda's Entyvio, and Janssen's Simponi Projected to Gain Ground in the Increasingly Competitive Ulcerative Colitis Market
By a News Reporter-Staff News Editor at Drug Week Results from a recent study just released by Spherix Global Insights reveal that US gastroenterologists project significant growth of Takeda's Entyvio, Janssen's Simponi, and Pfizer/ Hospira's infliximab biosimilar, Inflectra over the next six months. While the positive bumps to Entyvio and Simpon
Articles(s): 1 - 25 of 76     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415